Medicina clinica (English ed.)最新文献

英文中文

Trends in mortality in Spain, with a special focus on respiratory-related conditions in the midst of the COVID-19 pandemic

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.08.005

Adrián Peláez , Joan B. Soriano , María Rodrigo-García , José L. Peñalvo , Julio Ancochea , Esteve Fernández

Background and objective

The COVID-19 pandemic significantly increased the global burden of respiratory morbidity and mortality. In Spain, 2020 saw a 68.5% surge in deaths from respiratory diseases compared to 2019, largely due to COVID-19. This study aims to describe respiratory disease mortality in Spain from 2019 to 2022, focusing on the intersection of COVID-19, pre-existing respiratory conditions, and specific health determinants.

Materials and methods

We analyzed mortality data from the Spanish National Institute of Statistics (INE), covering 102 causes of death, including tuberculosis, COVID-19, and lung cancer as respiratory-related conditions. The analysis considered absolute death counts and proportions by sex, age, and region, along with percentage changes in proportional mortality. Logistic regression models were used to identify factors potentially associated with COVID-19 and respiratory-specific mortality.

Results

In 2022, Spain reported 98,128 deaths from respiratory diseases, accounting for 21.1% of all deaths and ranking as the second leading cause of death after cardiovascular diseases. Although deaths due to COVID-19 decreased in 2021 and 2022, there was a notable rise in other respiratory causes, indicating a lasting post-pandemic impact. Factors linked to higher mortality included male gender, older age, being divorced, and residing in urban areas, with significant regional variability.

Conclusions

Despite overall mortality returning to pre-pandemic levels, this study highlights a significant increase in respiratory disease deaths in Spain in 2022 compared to 2019.

{"title":"Trends in mortality in Spain, with a special focus on respiratory-related conditions in the midst of the COVID-19 pandemic","authors":"Adrián Peláez , Joan B. Soriano , María Rodrigo-García , José L. Peñalvo , Julio Ancochea , Esteve Fernández","doi":"10.1016/j.medcle.2024.08.005","DOIUrl":"10.1016/j.medcle.2024.08.005","url":null,"abstract":"<div><h3>Background and objective</h3><div>The COVID-19 pandemic significantly increased the global burden of respiratory morbidity and mortality. In Spain, 2020 saw a 68.5% surge in deaths from respiratory diseases compared to 2019, largely due to COVID-19. This study aims to describe respiratory disease mortality in Spain from 2019 to 2022, focusing on the intersection of COVID-19, pre-existing respiratory conditions, and specific health determinants.</div></div><div><h3>Materials and methods</h3><div>We analyzed mortality data from the Spanish National Institute of Statistics (INE), covering 102 causes of death, including tuberculosis, COVID-19, and lung cancer as respiratory-related conditions. The analysis considered absolute death counts and proportions by sex, age, and region, along with percentage changes in proportional mortality. Logistic regression models were used to identify factors potentially associated with COVID-19 and respiratory-specific mortality.</div></div><div><h3>Results</h3><div>In 2022, Spain reported 98,128 deaths from respiratory diseases, accounting for 21.1% of all deaths and ranking as the second leading cause of death after cardiovascular diseases. Although deaths due to COVID-19 decreased in 2021 and 2022, there was a notable rise in other respiratory causes, indicating a lasting post-pandemic impact. Factors linked to higher mortality included male gender, older age, being divorced, and residing in urban areas, with significant regional variability.</div></div><div><h3>Conclusions</h3><div>Despite overall mortality returning to pre-pandemic levels, this study highlights a significant increase in respiratory disease deaths in Spain in 2022 compared to 2019.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"164 1","pages":"Pages 1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of bone disease in cystic fibrosis

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.05.030

Victoria Contreras-Bolívar , María Carmen Andreo-López , Manuel Muñoz-Torres

With the increased life expectancy of people with cystic fibrosis (CF), clinical attention has focused on prevention and treatment of non-pulmonary comorbidities. CF-related bone disease (CFBD) is a common complication and leads to increased fracture rates. Dual energy X-ray absorptiometry (DXA) is the recommended and gold standard technique to identify and monitor bone health. However, DXA has limitations because of its two-dimensional nature. Complementary tools to DXA are available, such as trabecular bone score (TBS) and vertebral fracture assessment (VFA). Quantitative computed tomography (QCT), magnetic resonance imaging (MRI) and quantitative ultrasound (QUS) may also be useful.

引用次数: 0

Pyoderma gangrenosum and IgA Myeloma

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.12.001

Javier de la Iglesia Martin, Marta Alegre, Jose Manuel Mascaró Galy

引用次数: 0

Successful rapid one-bag desensitization protocol toagalsidase-beta after a severe reaction

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.07.021

Filip Skrabski , Berta Valor-Llácer , Vanessa Gázquez

引用次数: 0

Diabetes insipidus as presentation of hypothalamus and infundibulum involvement of mantle cell lymphoma relapse

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.05.032

Pedro Parra Caballero , Jaime Bustos Carpio , Jimena Cannata-Ortiz

引用次数: 0

Kaposi's sarcoma

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.03.031

Jullio C. Salas-Alanís , Mauricio Salas-Garza , María G. Moreno-Treviño , Sebastián Márquez-Murillo , Gerardo Rivera-Silva

引用次数: 0

Multi-drug resistant (MDR) Pseudomonas aeruginosa ventriculitis associated with external ventricular drain

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.06.015

Paloma Albacete Ródenas , Inmaculada de Dios Chacón , Daniela García Huertas

引用次数: 0

Stercoraceal colitis as a complication of chronic constipation

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.07.019

Myrian González Álvarez, Ana Latorre Díez, Miguel Ángel Núñez Viejo

引用次数: 0

Rhupus syndrome: description of 9 cases with special atenttion to the HLA-DR genotype

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.09.003

Andrés Pérez Hurtado , Isabel Martínez Cordellat , Roxana González Mazario , Elene Grau García , José Andrés Román Ivorra

Background and objectives

Rhupus is a very rare syndrome of overlapping rheumatoid arthritis and systemic lupus erythematosus, characterized by the presence of erosive polyarthritis associated with symptoms and signs of systemic lupus erythematosus and the presence of high specificity autoantibodies. The analysis of HLA-DR molecules would allow us to genetically characterize patients diagnosed with rhupus, being able to differentiate them from the HLA-DR profile of patients with rheumatoid arthritis and systemic lupus erythematosus.

Materials and methods

Cross-sectional observational study of 9 patients diagnosed with Rhupus in whom the HLA-DR genotype was genetically characterized.

Results

Rhupus is usually more frequent in women with initial diagnosis of RA. The most frequent clinical manifestations are articular and, serologically, ANA, RF and anti-CCP positivity stand out. The most frequent HLA-DR were HLA-DR1, HLA-DR3, HLA-DR4, HLA-DR7 and HLA-DR13.

Conclusions

A higher proportion of HLA-DR1 and DR9 was observed in patients with Rhupus compared to RA and SLE, as well as a lower proportion of HLA-DR2, DR6 and DR8, which would help the early characterization of these patients prior to the overlap diagnosis.

{"title":"Rhupus syndrome: description of 9 cases with special atenttion to the HLA-DR genotype","authors":"Andrés Pérez Hurtado , Isabel Martínez Cordellat , Roxana González Mazario , Elene Grau García , José Andrés Román Ivorra","doi":"10.1016/j.medcle.2024.09.003","DOIUrl":"10.1016/j.medcle.2024.09.003","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Rhupus is a very rare syndrome of overlapping rheumatoid arthritis and systemic lupus erythematosus, characterized by the presence of erosive polyarthritis associated with symptoms and signs of systemic lupus erythematosus and the presence of high specificity autoantibodies. The analysis of HLA-DR molecules would allow us to genetically characterize patients diagnosed with rhupus, being able to differentiate them from the HLA-DR profile of patients with rheumatoid arthritis and systemic lupus erythematosus.</div></div><div><h3>Materials and methods</h3><div>Cross-sectional observational study of 9 patients diagnosed with Rhupus in whom the HLA-DR genotype was genetically characterized.</div></div><div><h3>Results</h3><div>Rhupus is usually more frequent in women with initial diagnosis of RA. The most frequent clinical manifestations are articular and, serologically, ANA, RF and anti-CCP positivity stand out. The most frequent HLA-DR were HLA-DR1, HLA-DR3, HLA-DR4, HLA-DR7 and HLA-DR13.</div></div><div><h3>Conclusions</h3><div>A higher proportion of HLA-DR1 and DR9 was observed in patients with Rhupus compared to RA and SLE, as well as a lower proportion of HLA-DR2, DR6 and DR8, which would help the early characterization of these patients prior to the overlap diagnosis.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"164 1","pages":"Pages 16-19"},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143093338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The threat of dengue in Spain

Medicina clinica (English ed.)

Pub Date : 2025-01-10 DOI: 10.1016/j.medcle.2024.08.004

José-Manuel Ramos-Rincón , Ángel Giménez-Richarte

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Medicina clinica (English ed.)

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀